-
Hexetidine and Oral Antiseptic Persistence
2026-10-08
The 1981 study by Roberts and Addy compared hexetidine with chlorhexidine, alexidine, and cetylpyridinium chloride across laboratory susceptibility tests and short-term salivary outcomes. Its central contribution was showing that apparent antimicrobial potency, resistance to oral matrix effects, and persistence in saliva are related but distinct properties, helping explain why in vitro results do not directly predict dental plaque reduction.
-
MVC, RhoA/ROCK1, and Tight-Junction Entry
2026-10-08
Ren et al. identify a host-cell mechanism in which MVC VP2 interacts with ROCK1 and activates the RhoA/ROCK1/MLC2 axis, altering tight-junction organization and exposing occludin during infection. The work connects cytoskeletal signaling with viral entry, while its inhibitor and localization data support a mechanistic model that remains primarily in vitro and requires validation in additional canine systems.
-
Amplex Red in Peroxidase and P450 Research
2026-10-07
Amplex Red, also known as 10-Acetyl-3,7-dihydroxyphenoxazine, is a fluorogenic reporter for hydrogen peroxide-dependent oxidation and peroxidase activity. This overview examines its research context, conceptual applications, findings from a cytochrome P450 screening study, evidence strength, and limits on interpreting fluorescence as a direct measure of reactive oxygen species.
-
Sisomicin: What a 1984 Review Established
2026-10-07
Paul Noone’s 1984 review synthesized the antibacterial activity, resistance profile, pharmacokinetics, and therapeutic experience of Sisomicin, netilmicin, and dibekacin. Its central contribution was comparative interpretation: Sisomicin showed strong activity against several Gram-negative organisms, including selected Pseudomonas aeruginosa isolates, but remained vulnerable to many aminoglycoside-inactivating enzymes.
-
Coumestrol and Ferroptosis in Rheumatoid Arthritis
2026-10-06
A source-grounded overview of Coumestrol research in rheumatoid arthritis, focusing on fibroblast-like synoviocytes, ferroptosis, PMAIP1 stability, nuclear receptor context, evidence strength, and translational limitations.
-
Annexin V-FITC/7-AAD Apoptosis Kit Overview
2026-10-05
A concise, supplier-documented overview of APExBIO’s K1139 Annexin V-FITC/7-AAD Apoptosis Kit, its conceptual cell-death readout, and the limits of available evidence.
-
Bedaquiline at the Bioenergetic–Host Interface
2026-10-05
Bedaquiline offers a compelling framework for studying energy dependency across tuberculosis and cancer biology. This evidence-calibrated perspective connects its pathogen-directed mechanism with emerging host-directed therapy research while distinguishing established findings from translational hypotheses.
-
EdU Flow Cytometry: Research Context and Evidence
2026-10-04
A source-grounded overview of EdU-based DNA synthesis measurement, its conceptual relevance to bladder cancer research, and the evidence limits surrounding the EdU Flow Cytometry Assay Kits (Cy3).
-
Cefodizime and the Translational AMR Evidence Gap
2026-10-03
Cefodizime offers a useful translational lens for connecting penicillin-binding protein biology, antimicrobial resistance surveillance, and host-response research. Evidence from urban rodents in Hanoi shows why broad-spectrum activity must be interpreted alongside resistance context, organism boundaries, and study provenance.
-
Meropenem Assays for Resistance Transmission Models
2026-10-02
Meropenem is a β-lactam antibiotic carbapenem with value beyond routine susceptibility testing. This article shows how transmission-aware assay design can separate drug activity, carbapenemase genetics, plasmid mobility, and infection-model outcomes.
-
Cyclosporin A (B1922): Practical Workflow Guide
2026-10-01
This guide explains how to use Cyclosporin A (B1922) in solvent-based cellular and biochemical workflows involving cyclophilin inhibition, calcineurin-NFAT signaling, immune suppression, and apoptosis modulation. It is not suitable for aqueous-only protocols without a validated formulation, and product-listed conditions should be treated as starting points rather than universal assay settings.
-
Meropenem Assay Design for Resistance Research
2026-10-01
Meropenem assay design should separate target engagement, exposure, and resistance rather than treating susceptibility as a single endpoint. This guide translates β-lactam pharmacodynamics into practical workflows for septicemia treatment research, Gram-negative infection models, and carbapenem-resistant bacterial infections.
-
Sodium Dicloxacillin Monohydrate for MSSA Research
2026-09-30
Sodium dicloxacillin monohydrate is a narrow-spectrum β-lactam research compound for penicillin-binding protein studies involving methicillin-sensitive Staphylococcus aureus. Reported potency depends on strain, cellular compartment, and pH, so experimental interpretation requires explicit assay conditions and validated controls.
-
Ceftolozane-Tazobactam in Nosocomial Pneumonia
2026-09-30
The reference article explains how ceftolozane-tazobactam combines structural protection from AmpC hydrolysis with focused antipseudomonal activity and time-dependent pharmacology. Its synthesis of susceptibility, PK/PD, and ASPECT-NP evidence supports the combination as an important option for nosocomial pneumonia while also clarifying the limits of extrapolating in vitro activity to clinical treatment.
-
EMD638683: Practical SGK1 Inhibitor Workflows
2026-09-29
EMD638683 supports mechanism-focused studies spanning endothelial stiffness, NDRG1 target engagement, tumor-cell signaling, and hypertension models. This guide translates published SGK1 biology into practical dosing, controls, readouts, formulation choices, and troubleshooting steps.